SCHEMBL75146

SCHEMBL75146

CCOc1ccccc1C1(O)C(=O)Nc2ccc(C#N)cc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.50
RXFP1 Q9HBX9 1/20 0.41
PGR P06401 2/20 0.40
TRPV4 Q9HBA0 1/20 0.40
MEN1 O00255 1/20 0.39
AVPR1B P47901 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
BRD4 O60885 1/20 0.37
TP53 P04637 1/20 0.36
PDK2 Q15119 1/20 0.36
PDE5A O76074 1/20 0.36
BACE1 P56817 1/20 0.36
POLB P06746 1/20 0.36
CASP6 P55212 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
ALOX12 P18054 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2679629 0.87 KMT2A (0.67) KMT2APGRMEN1BRD4PDK2
SCHEMBL17260274 0.85 AVPR1B (0.44) KMT2APGRTRPV4AVPR1BBRD4
SCHEMBL1795281 0.84 TRPV4 (0.43) KMT2ARXFP1PGRTRPV4AVPR1B
SCHEMBL75334 0.84 PGR (0.40) KMT2ARXFP1PGRTRPV4MEN1
SCHEMBL1479873 0.84 AVPR1B (0.42) KMT2APGRTRPV4MEN1AVPR1B
SCHEMBL2494879 0.82 KMT2A (0.53) KMT2APGRMEN1BRD4TP53
SCHEMBL74450 0.82 KMT2A (0.53) KMT2AMEN1BRD4TP53PDK2
SCHEMBL4510489 0.82 RXFP1 (0.42) KMT2ARXFP1PGRTRPV4MEN1
SCHEMBL1464852 0.81 KMT2A (0.59) KMT2APGRMEN1BRD4KDM4E
SCHEMBL1801335 0.79 RXFP1 (0.40) KMT2ARXFP1PGRTRPV4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338590-B2 Substituted oxindole derivatives and medicaments containing the same ABBOTT GMBH & CO. KG (DE) 2012-12-25 US disclosed
US-8202870-B2 Substituted oxindole derivatives, medicaments containing the latter and use thereof ABBOTT GMBH & CO. KG (DE) 2012-06-19 US disclosed
US-20120136001-A1 SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2012-05-31 US disclosed
US-8129389-B2 Substituted oxindole derivatives, medicaments containing the latter and use thereof ABBOTT GMBH & CO. KG (DE) 2012-03-06 US disclosed
US-20110257194-A1 SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME ABBOTT GMBH & CO. KG (DE) 2011-10-20 US disclosed
US-7951807-B2 Substituted oxindol derivatives and medicaments containing the same ABBOTT GMBH & CO. KG (DE) 2011-05-31 US disclosed
US-20090215790-A1 Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2009-08-27 US disclosed
US-20090186904-A1 Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof ABBOTT GMBH & CO. KG 2009-07-23 US disclosed
US-20090005397-A1 Substituted Oxindol Derivatives and Medicaments Containing the Same ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2009-01-01 US disclosed
EP-1866304-A2 SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF Abbott GmbH & Co. KG (DE) 2007-12-19 EP disclosed
EP-1861390-A1 SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF Abbott GmbH & Co. KG (DE) 2007-12-05 EP disclosed
WO-2006100080-A1 SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF ABBOTT GMBH & CO. KG (DE) 2006-09-28 WO disclosed
WO-2006100081-A2 SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF ABBOTT GMBH & CO. KG (DE) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005397-A1 Substituted Oxindol Derivatives and Medicaments Containing the Same OXTR, AVPR2, AVPR1B KMT2A 4350/4885RXFP1 35/4885PGR 412/4885
US-20110257194-A1 SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME OXTR, AVPR2, AVPR1B KMT2A 4284/4885RXFP1 55/4885PGR 480/4885
US-20090215790-A1 Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof OXTR, AVPR2, AVPR1B KMT2A 4000/4885RXFP1 61/4885PGR 317/4885
US-20090186904-A1 Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof OXTR, AVPR2, AVPR1B KMT2A 3892/4885RXFP1 65/4885PGR 449/4885
US-20120136001-A1 SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF OXTR, AVPR2, AVPR1B KMT2A 3892/4885RXFP1 65/4885PGR 449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.